Cited 0 times in
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건민 | - |
dc.date.accessioned | 2022-09-14T01:27:48Z | - |
dc.date.available | 2022-09-14T01:27:48Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190463 | - |
dc.description.abstract | Purpose: YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovarian function suppression compared to capecitabine. However, the number of tamoxifen-sensitive premenopausal patients was small because most recurrences occurred early during adjuvant endocrine therapy (ET), with tamoxifen being the only drug used; hence, the data for these patients were limited. Here we present a subgroup analysis according to tamoxifen sensitivity from the YoungPEARL study. Materials and methods: Patients were randomized 1:1 to receive palbociclib+ET (oral exemestane 25 mg/day for 28 days, palbociclib 125 mg/day for 21 days, plus leuprolide 3.75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1,250 mg/m2 twice daily for 14 days every 3 weeks). Tamoxifen resistance was defined as: relapse while on adjuvant tamoxifen, relapse within 12 months of completing adjuvant tamoxifen, or progression while on first-line tamoxifen within 6 months for MBC. Results: In total, 184 patients were randomized and 178 were included in the modified intention-to-treat population. PFS improvement in the palbociclib+ET group was observed in tamoxifen-sensitive patients (hazard ratio, 0.38; 95% confidence interval, 0.12 to 1.19). Furthermore, palbociclib+ET prolonged median PFS compared with capecitabine in tamoxifen-sensitive (20.5 months vs. 12.6 months) and tamoxifen-resistant (20.1 months vs. 14.5 months) patients. Palbociclib+ET demonstrated a higher rate of objective response, disease control, and clinical benefit in tamoxifen-sensitive patients. Conclusion: This post hoc exploratory analysis suggests that palbociclib+ET is a promising therapeutic option for premenopausal HR+/HER2- MBC patients irrespective of tamoxifen sensitivity. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Androstadienes / pharmacology | - |
dc.subject.MESH | Androstadienes / therapeutic use | - |
dc.subject.MESH | Antineoplastic Agents, Hormonal / pharmacology | - |
dc.subject.MESH | Antineoplastic Agents, Hormonal / therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / pharmacology* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Breast Neoplasms / mortality | - |
dc.subject.MESH | Breast Neoplasms / pathology | - |
dc.subject.MESH | Breast Neoplasms / therapy* | - |
dc.subject.MESH | Chemotherapy, Adjuvant / methods | - |
dc.subject.MESH | Clinical Trials, Phase II as Topic | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mastectomy | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multicenter Studies as Topic | - |
dc.subject.MESH | Neoplasm Recurrence, Local / mortality | - |
dc.subject.MESH | Neoplasm Recurrence, Local / pathology | - |
dc.subject.MESH | Neoplasm Recurrence, Local / therapy* | - |
dc.subject.MESH | Piperazines / pharmacology* | - |
dc.subject.MESH | Piperazines / therapeutic use | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Protein Kinase Inhibitors / pharmacology | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use | - |
dc.subject.MESH | Pyridines / pharmacology* | - |
dc.subject.MESH | Pyridines / therapeutic use | - |
dc.subject.MESH | Randomized Controlled Trials as Topic | - |
dc.subject.MESH | Receptor, ErbB-2 / analysis | - |
dc.subject.MESH | Receptors, Estrogen / analysis | - |
dc.subject.MESH | Receptors, Estrogen / metabolism | - |
dc.subject.MESH | Receptors, Progesterone / analysis | - |
dc.subject.MESH | Receptors, Progesterone / metabolism | - |
dc.subject.MESH | Tamoxifen / pharmacology* | - |
dc.subject.MESH | Tamoxifen / therapeutic use | - |
dc.title | Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jiyun Lee | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Kyung Hae Jung | - |
dc.contributor.googleauthor | Seok Yun Kang | - |
dc.contributor.googleauthor | In Hae Park | - |
dc.contributor.googleauthor | Jee Hyun Kim | - |
dc.contributor.googleauthor | Hee Kyung Ahn | - |
dc.contributor.googleauthor | Yeon Hee Park | - |
dc.identifier.doi | 10.4143/crt.2020.1246 | - |
dc.contributor.localId | A00287 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 33332933 | - |
dc.subject.keyword | Breast neoplasms | - |
dc.subject.keyword | CDK4/6 inhibitor | - |
dc.subject.keyword | Endocrine therapy | - |
dc.subject.keyword | Palbociclib | - |
dc.subject.keyword | Tamoxifen | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | 김건민 | - |
dc.citation.volume | 53 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 695 | - |
dc.citation.endPage | 702 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.53(3) : 695-702, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.